Artificial Intelligence May Discover the Next Blockbuster Drug
AI is revolutionizing countless industries, but its biggest impact may be felt in medicine. Machine learning has proved capable of identifying signs of disease in medical images and records, and it may become invaluable for analyzing vast genomic data sets for clues as to the origins of different disorders. Benevolent AI, headquartered in London, is working to apply the latest AI techniques to the identification and development of novel drug compounds. The company’s CEO, Ken Mulvaney, met with MIT Technology Review’s senior editor for AI, Will Knight, to discuss AI’s relevance to drug discovery and medicine, and to talk about his company’s ambitious plans.
Keep Reading
Most Popular
Large language models can do jaw-dropping things. But nobody knows exactly why.
And that's a problem. Figuring it out is one of the biggest scientific puzzles of our time and a crucial step towards controlling more powerful future models.
OpenAI teases an amazing new generative video model called Sora
The firm is sharing Sora with a small group of safety testers but the rest of us will have to wait to learn more.
Google’s Gemini is now in everything. Here’s how you can try it out.
Gmail, Docs, and more will now come with Gemini baked in. But Europeans will have to wait before they can download the app.
This baby with a head camera helped teach an AI how kids learn language
A neural network trained on the experiences of a single young child managed to learn one of the core components of language: how to match words to the objects they represent.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.